NCT05082727View on ClinicalTrials.gov

Safety and Efficacy of Softgel KOVIR (TD0068) in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

September 15, 2022

Study Completion Date

November 15, 2022

Conditions
COVID-19
Interventions
DIETARY_SUPPLEMENT

KOVIR (TD0068) oral softgel

KOVIR (TD0068) is a softgel containing Allium sativum extract 270mg, Colostrum156.4 mg, fine powder mixed herbs 43.6mg

DIETARY_SUPPLEMENT

Placebo oral softgel

Placebo

Trial Locations (1)

Unknown

RECRUITING

National hospital for tropical diseases, Hà Nội

Sponsors
All Listed Sponsors
collaborator

Vietstar Biomedical Research

INDUSTRY

lead

Sao Thai Duong Joint Stock Company

INDUSTRY

NCT05082727 - Safety and Efficacy of Softgel KOVIR (TD0068) in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR) | Biotech Hunter | Biotech Hunter